Medicare AdvantageCoverageLow impact
MA08.126b, Inebilizumab-cdon (Uplizna)
Independence Blue Cross·Neurology·Pharmacy
Effective date
Apr 30, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.126b for Inebilizumab-cdon (Uplizna) has been reissued and will be effective April 30, 2025. This is a pharmacy policy update that may affect coverage or authorization requirements for this specialty medication used to treat neuromyelitis optica spectrum disorders.
Action Required
By April 30, 2025: Review the complete policy document at the provided URL to understand specific coverage changes for Inebilizumab-cdon (Uplizna). Update prior authorization procedures and billing protocols as specified in the full policy. Notify providers who treat neuromyelitis optica spectrum disorders of any new requirements.